Newsfeeds - Spark Newswire

2 minute read

Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line

Today, 3:15 PM

Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed…

APLS

1 minute read

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $70

By vishwanath@benzinga.com

Today, 3:15 PM

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $85 to $70.

APLS

4 minute read

Apellis Announces Phase 3 DERBY Study In Geographic Atrophy Did Not Meet Primary Endpoint, OAKS Study Met Primary Endpoint

By Bill Haddad

Today, 3:15 PM

OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052),

APLS

1 minute read

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 3:15 PM

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

APLS

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 19, 2021

By Benzinga Insights

Today, 3:15 PM

AMAT

1 minute read

Wedbush Upgrades Apellis Pharmaceuticals to Outperform

By Benzinga Newsdesk

Today, 3:15 PM

Wedbush analyst Laura Chico upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Neutral to Outperform.

APLS

1 minute read

Jefferies Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $74

By Benzinga Newsdesk

Today, 3:15 PM

Jefferies analyst Chris Howerton initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy rating and announces Price Target of $74.

APLS

1 minute read

Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $50

By Benzinga Newsdesk

Today, 3:15 PM

Credit Suisse analyst Tiago Fauth maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $44 to $50.

APLS

1 minute read

Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Lowers Price Target to $102

By Benzinga Newsdesk

Today, 3:15 PM

Raymond James analyst Steven Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and lowers the price target from $115 to $102.

APLS

1 minute read

Earnings

Recap: Apellis Pharmaceuticals Q2 Earnings

By Benzinga Insights

Today, 3:15 PM

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 73.25% year over year to ($2.72), which missed the estimate of ($1.70).

APLS